Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimating the case fatality ratio of the COVID-19 epidemic in China

View ORCID ProfileXing Wang, View ORCID ProfileZihui Ma, View ORCID ProfileYi Ning, View ORCID ProfileChen Chen, Rujin Chen, Qiwen Chen, View ORCID ProfileHeng Zhang, View ORCID ProfileChunming Li, View ORCID ProfileYan He, Tao Wang, Cheng Tong, Junqing Wu, Yuyan Li, View ORCID ProfileHandong Ma, View ORCID ProfileShaodian Zhang, View ORCID ProfileHongxin Zhao
doi: https://doi.org/10.1101/2020.02.17.20023630
Xing Wang
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
2NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Public Health School, Fudan University, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xing Wang
Zihui Ma
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zihui Ma
Yi Ning
3Meinian Institute of Health, Beijing, China
4Peking University Health Science Center Meinian Public Health Research Institute, Beijing, China
ScD MPH MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yi Ning
Chen Chen
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
5National Institute of Environmental and Health, Chinese Center for Disease Control and Prevention, Bejing 100050, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chen Chen
Rujin Chen
6Donor Service, Shanghai Blood Center, Shanghai, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiwen Chen
7Department of Integrative Oncology, Shanghai Cancer Center, Shanghai Medical School, Fudan University, Shanghai, China
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heng Zhang
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Heng Zhang
Chunming Li
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chunming Li
Yan He
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yan He
Tao Wang
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MCS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Tong
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junqing Wu
8NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuyan Li
8NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Handong Ma
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
9Department of Computer Science, Shanghai Jiao Tong University, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Handong Ma
  • For correspondence: zhx{at}zhaohx.com handong{at}synyi.com shaodian{at}synyi.com
Shaodian Zhang
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shaodian Zhang
  • For correspondence: zhx{at}zhaohx.com handong{at}synyi.com shaodian{at}synyi.com
Hongxin Zhao
1Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hongxin Zhao
  • For correspondence: zhx{at}zhaohx.com handong{at}synyi.com shaodian{at}synyi.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Corona Virus Disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China since late December 2019. Crude case fatality ratio (CFR) with dividing the number of known deaths by the number of confirmed cases does not represent the true CFR and might be off by orders of magnitude. We aim to provide a precise estimate of the CFR of COVID-19 using statistical models at the early stage of the epidemic.

Methods We extracted data from the daily released epidemic report published by the National Health Commission P. R. China from 20 Jan 2020, to 1 March 2020. Competing risk model was used to obtain the cumulative hazards for death, cure, and cure-death hazard ratio. Then the CFR was estimated based on the slope of the last piece in joinpoint regression model, which reflected the most recent trend of the epidemic.

Results As of 1 March 2020, totally 80,369 cases were diagnosed as COVID-19 in China. The CFR of COVID-19 were estimated to be 70.9% (95% CI: 66.8%-75.6%) during Jan 20-Feb 2, 20.2% (18.6%-22.1%) during Feb 3-14, 6.9% (6.4%-7.4%) during Feb 15-23, 1.5% (1.4%-1.6%) during Feb 24-March 1 in Hubei province, and 20.3% (17.0%-25.3%) during Jan 20-28, 1.9% (1.8%-2.1%) during Jan 29-Feb 12, 0.9% (0.8%-1.1%) during Feb 13-18, 0.4% (0.4%-0.5%) during Feb 19-March 1 in other areas of China, respectively.

Conclusions Based on analyses of public data, we found that the CFR in Hubei was much higher than that of other regions in China, over 3 times in all estimation. The CFR would follow a downwards trend based on our estimation from recently released data. Nevertheless, at early stage of outbreak, CFR estimates should be viewed cautiously because of limited data source on true onset and recovery time.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding was received for the research reported in the article.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data, models, and code generated or used during the study appear in the submitted article.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 03, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimating the case fatality ratio of the COVID-19 epidemic in China
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimating the case fatality ratio of the COVID-19 epidemic in China
Xing Wang, Zihui Ma, Yi Ning, Chen Chen, Rujin Chen, Qiwen Chen, Heng Zhang, Chunming Li, Yan He, Tao Wang, Cheng Tong, Junqing Wu, Yuyan Li, Handong Ma, Shaodian Zhang, Hongxin Zhao
medRxiv 2020.02.17.20023630; doi: https://doi.org/10.1101/2020.02.17.20023630
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Estimating the case fatality ratio of the COVID-19 epidemic in China
Xing Wang, Zihui Ma, Yi Ning, Chen Chen, Rujin Chen, Qiwen Chen, Heng Zhang, Chunming Li, Yan He, Tao Wang, Cheng Tong, Junqing Wu, Yuyan Li, Handong Ma, Shaodian Zhang, Hongxin Zhao
medRxiv 2020.02.17.20023630; doi: https://doi.org/10.1101/2020.02.17.20023630

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)